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Supplementary Note 1: inclusion criteria 
 
There are no validated diagnostic criteria for EGPA. The 2012 Chapel Hill 
Consensus Conference (CHCC) described EGPA as a disease characterized 
by ‘eosinophil-rich and necrotizing granulomatous inflammation often involving 
the respiratory tract, and necrotizing vasculitis predominantly affecting small 
to medium vessels, and associated with asthma and eosinophilia’1. However, 
as acknowledged in the CHCC publication itself, the product of the CHCC is a 
nomenclature system, and not diagnostic or classification criteria, and thus 
the CHCC definition is not suitable for diagnosis. 
 
The emphasis on a histopathological definition of EGPA can be traced back to 
Churg and Strauss's original description of the syndrome, which was made 
largely on the basis of post-mortem studies of patients with untreated long-
standing disease2. In modern clinical practice, overt vasculitis is much harder 
to detect. In a series of 23 EGPA patients published by Reid et al in 1998, 
only 4 met the original histopathological criteria of Churg and Strauss3. There 
are multiple reasons for this. Many patients who present with EGPA are 
already on chronic corticosteroid therapy for asthma control. Patients who 
present with organ- or life-threatening disease and the typical clinical, 
radiological, hematological and serological findings are treated empirically 
with high-dose corticosteroids, and so if a biopsy is taken it is usually after 
treatment has been instituted. Affected tissues may not be easily accessible 
for biopsy, and the tissue samples that are obtained are small, making 
vasculitis much harder to detect than on post-mortem studies.  
 
Lanham et al. first identified the limitations of diagnostic criteria that focus 
narrowly on fulfilling the pathological features of necrotizing vasculitis, 
extravascular granulomata and tissue infiltration by eosinophils, since these 
pathological features often do not co-exist spatially or temporally, or indeed at 
all4.  In recognition of the limitations of diagnostic criteria that required 
histopathological evidence of necrotizing vasculitis and granulomata, Lanham 
et al proposed diagnostic criteria4 that required the presence of asthma, 
 5 
peripheral blood eosinophilia (peak count >1.5x109/L) and systemic vasculitis 
involving two or more extra-pulmonary organs. The evidence of vasculitis 
could be clinical or radiological, and did not have to be confirmed 
histopathologically. These criteria are not widely used, as they fail to identify 
the many patients who do not have overt evidence of vasculitis. 
 
The 1990 American College of Rheumatology (ACR) classification criteria 
were designed to classify patients with already documented vasculitis5. The 
ACR criteria were derived through analysis of 20 EGPA patients and 787 
patients with other forms of vasculitis, in which multivariate modelling was 
used to select a set of 6 features that most effectively discriminated EGPA 
from other forms of vasculitis when 4 or more were present. In this dataset, 
the presence of 4 or more of the 6 yielded a sensitivity of 85% and a 
specificity of 99.7%. However, it is important to note the ACR criteria were not 
developed for making a diagnosis in individual patients and have not been 
validated for this purpose6. Indeed, The ACR criteria for other vasculitides 
developed concurrently using this dataset have been shown to perform poorly 
when used for diagnosis7. In the series of 23 patients with a clinical diagnosis 
of EGPA reported by Reid et al, only 14 met the ACR criteria3. Therefore the 
ACR criteria are unsuitable for most clinical studies. 
 
More appropriate for use in clinical or genetic studies are the recently 
developed diagnostic criteria used in the Phase III clinical trial “Study to 
Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis 
With Polyangiitis” (MIRRA: Supplementary Table 1)8. These define EGPA 
diagnosis based on the history or presence of both asthma and eosinophilia 
(>1.0 \times 109/L and/or > 10% of leukocytes) plus at least two additional 
features of EGPA. Of note, the MIRRA criteria include a wider range of clinical 
features than the ACR criteria (e.g. cardiac involvement and 
glomerulonephritis), and also the results of ANCA testing, which was not 
widely available at the time the ACR criteria were developed. 
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Supplementary Note 2: comparison of genetic similarity of ANCA 
negative EGPA and MPO positive EGPA to asthma 
 
We compared Z-scores from the MPO+ vs control analysis to Z-scores from 
asthma (which we denote Za) using the test statistic Xp, defined below. To 
assess whether Xp, was significant, we compared its observed value to 
distributions estimated under 3 sampling schema. We repeatedly resampled 
159 samples with the same geographic distribution as the MPO+ cases, 
without replacement, under the following three schema: 
 
A) from ANCA- cases, using all controls 
B) from all EGPA cases, using all controls 
C) from controls, using remaining controls as the control set. 
 
For each draw i, we conducted a GWAS case/control analysis using the same 
methodology and covariates as for the MPO+/control analysis and calculated 
a value for Xp,, to generate sets of test statistics XA, XB, XC from draws under 
schemas A, B and C respectively.  
 
We estimated a p-value for the deviation of Xp from what would be expected 
under a null hypothesis H0hom of non-HLA genetic homogeneity between 





Under H0hom, by assumption, the mean of XA is equal to the expected value of 
Xp. The variance of XA underestimates the sampling variance of Xp, since 
there are fewer ANCA- cases than EGPA cases in total, so we estimated the 
sampling variance of Xp with the variance of XB. We note that we take the 
sampling variance of Xp to correspond to a sampling schema of ‘select 159 
cases from the 534 available EGPA cases’ rather than ‘sample 159 cases 
!"|$%&'( ∼ * +,-. !/ , 1-2 !3  1 
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from the EGPA population’. Since Xp is an average across multiple SNPs, we 
assumed a normal sampling distribution for Xp under CLT. 
 
Using this schema, we obtained a p-value of 0.033 against H0hom, indicating 
reasonable evidence for differential genetic basis between MPO+ and ANCA- 
EGPA outside the MHC region. Xp was typical of the values XC (quantile 
0.46), so we were unable to determine if MPO+ EGPA had any heritability 
outside the MHC region on the basis of this analysis. Densities of XA, XB, and 
XC compared to Xp are shown in Supplementary Figure 5. When the MHC 
region was included, MPO+ EGPA was not significantly more or less similar to 
asthma than ANCA- EGPA (p=0.34). 
 
We show that EGPA and asthma share associated variants (Table 2, 
Supplementary Table 7). Therefore the question arises as to whether the 
variants driving the difference in genetic architecture between ANCA- and 
MPO+ EGPA are or are not those associated with asthma. Expressed another 
way, are the two EGPA subsets genetically distinct because one subset more 
closely resembles asthma, or because they are simply intrinsically different, 
independent of any relationship with asthma? To address this, we chose a 
test statistic so as to be maximally sensitive to joint association with asthma 
and the EGPA subtype (see below), but that retains power to detect different 
genetic architectures between ANCA- and MPO+ EGPA at non-asthma 
associated variants. In other words, the value of the test statistic generally 
reflects 'similarity to asthma' but is also responsive to 'greater overall 
heritability'. 
 
If the different genetic architectures between ANCA- and MPO+ EGPA were 
primarily due to different effect sizes at non-asthma associated SNPs, then 
we would expect that the difference would be largely retained if we removed 
any dependence between Z scores for asthma and Z scores for the EGPA 
subtype. To check this, we reproduced test statistics XA, Xp in the same 
 with the Za scores randomly shuffled to give test statistics XA’, Xp’. 
This removed any dependence between the sets of Z scores, but retained the 
marginal distributions of Z scores for asthma and for the EGPA subtypes. We 
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found that both XA’ and Xp’ were indistinguishable from XC (quantile of 
mean(XA’) in XC  = 0.95, quantile of mean(Xp’) in XC = 0.94), by contrast to XA 
and Xp which were significantly different from XC. This indicated that the 
observed difference in genetic architecture between MPO+ and ANCA-EGPA 
was generally at variants which were also associated with asthma, and that 
the two subtypes differ in their genetic similarity to asthma. 
 
Graphically, a case in which the EGPA subtype showed no shared 
association with asthma would appear on Supplementary Figure 6 as a set 
of points displaced significantly from the origin along the x-axis, but not the y-
axis (variants associated with the EGPA subtype, but not with asthma), and a 
separate set of points displaced along the y-axis but not the x-axis (variants 
associated with asthma but not with the EGPA subtype). By contrast, variants 
associated with both asthma and the EGPA subtype would be displaced from 
the origin in both the x- and the y-axes simultaneously. 
 
Choice of statistic for pleiotropy 
To characterise the degree of pleiotropy between two phenotypes 
characterised by sets of Z scores, we sought a test statistic to detect 
concurrently high Z scores in both phenotypes. We considered two metrics for 
this; for Z-scores Za(i) for asthma and Zt(i) for the trait t under investigation at 






with α in {1,2}. Contours of the two test statistics are shown in 
Supplementary Figure 5.  
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The form of test statistic 2 was chosen so that SNPs with simultaneously high 
|Za| and |Zt| values would contribute to the statistic, but there would be 
minimal contribution from SNPs for which the point (Za, Zt) was near the x or y 
axis, even if one of Za , Zt were very large. 
 
We determined the statistic to use in the above analysis by determining which 
statistic best separated values XB from XC (defined as in the previous section), 
assessing separation by the value of a t-statistic score between the two sets 
of values. The best-performing test statistic was X1 with α=2. 
 
Concluding remarks 
In this analysis, we showed that ANCA-negative EGPA individuals have 
systematic genetic differences to MPO+ EGPA individuals outside of the MHC 
region, by establishing that the former showed greater pleiotropy with asthma. 
The phenotypic similarity of EGPA with asthma more generally indicates that 
these genetic differences are likely to correspond to clinically important 
pathophysiological processes. Given that our sampling maintained the 
geographic distribution of cases, this finding is unlikely to be confounded by 
geography. 
 
An obvious metric for assessment of pleiotropy between asthma and the 
EGPA subtype of interest is genetic correlation (rg). However, estimation of rg 
is complicated and estimates have prohibitively large variance when made 
using the small number of cases in this study. The aim of the analysis 
described above was simply to indicate genetic differences between the two 
EGPA subtypes, rather than to estimate genetic correlation. While the metric 
we used was somewhat simpler, it was difficult to compare its distribution 
across different study sizes, which necessitated the downsampling of ANCA-





Supplementary Figure 1. Manhattan plots showing only directly 
genotyped variants. P-values from BOLT-LMM. The horizontal red line 
indicates genome-wide significance (P 5x10-8). Significant variants are 
coloured in red. 
MPO+ve EGPA vs controls





































Supplementary Figure 2. Enrichment of asthma and eosinophil-
associated variants in EGPA. QQ plots of observed –log10 p-values for the 
association of genotype with EGPA (from BOLT-LMM) versus the expected –
log10 p-values under the null hypothesis of no association, conditional on 
varying degrees of association with A) asthma and B) eosinophil count. The 
MHC region has been excluded. Each circle represents a SNP. The coloured 
circles indicate sets of SNPs with increasing degrees of association with 
asthma (panel A) or eosinophil count (panel B). Their QQ-plots demonstrate 
progressive departure from the line y=x (dotted), indicating shared genetic 
architecture between EGPA and these traits. 
 
  





















































































































































































Supplementary Figure 3. Correlation of estimated effect sizes between 
primary and replication cohorts. Log (estimated ORs) (+/- 95% confidence 




Supplementary Figure 4. The MHC association with MPO+ve EGPA is 
localized to the Class II region. The MHC association signal in MPO+ 
EGPA in the primary cohort (A), replication cohort (B), MPO+ ANCA-
associated vasculitis (C from Lyons et al 9) and ANCA –ve EGPA (D). The 
positions of selected Class I and Class II loci are indicated (E), all co-
ordinates are from the hg19 genome build. (F) Imputation of classical alleles 





Supplementary Figure 5. Genetic similarity between EGPA subsets and 
asthma. The distributions of XA, XB, and XC under the sampling schemas 
described in the Supplementary Note are shown (MHC region removed). 
Greater right-displacement indicates greater genetic similarity with asthma. 
Samples from ANCA negative cases (A) show greater genetic similarity with 
asthma than do MPO+ cases (vertical line) or samples from all EGPA cases 























Supplementary Figure 6. Contour and density plots of test statistics for 
quantifying pleiotropy.  
Blue colours correspond to values near zero, yellow to large values. The 
contribution to X1 of a SNP with (Za, Zt)=(1,x) becomes arbitrarily large as 


























































































































































































Supplementary Figure 7. Genomic features and associations with other 
traits at non-MHC EGPA-associated loci. 
- Genomic positions from the hg19 genome build. 
- The position of selected RefSeq genes 
- DNA-DNA physical interactions identified by PCHi-C involving fine mapped 
SNPs in the indicated cell type 
- Associations with EGPA as a whole, and with MPO+ and ANCA- subsets. 
- PP= posterior probability from fine-mapping analysis. 
- ‘GWAS’ panel indicates trait-associated SNPs from the NHGRI GWAS 
Catalog (those with p-values < 1 × 10−5). IgAN= IgA nephropathy, RA= 
rheumatoid arthritis, Mn= peripheral blood monocyte count, PSC= primary 
sclerosing cholangitis, EC= peripheral blood eosinophil count, As= asthma, 
Eo= eosinophilic esophagitis, AR= allergic rhinitis, NC= neutrophil count, 
SLE = systemic lupus erythematosus, CD= Crohn’s disease, IBD= 
inflammatory bowel disease, Plt= platelet count, CeD= celiac disease, 
T1D= type 1 diabetes, MS= multiple sclerosis, T2D= type 2 diabetes 
mellitus, Vit= vitiligo, All*= allergic sensitization, L = liver enzyme levels, 
Sz= schizophrenia. 
- Histone marks from ENCODE are shown in green (GM12878 
lymphoblastoid cell line). H3K4me1 = associated with enhancer function 
and with active transcription. H3K4me3 = marker of promoters. H3K27ac = 
marker of active enhancers. 
 
(A) BCL2L11 region. PCHi-C data shown for neutrophils 10. 
(B) TSLP-WDR36 region. PCHi-C data shown for neutrophils 10. 
(C) CDK6 region. PCHi-C data shown for neutrophils 10. 
(D) 10p14 intergenic region. PCHi-C data shown for naive CD4 T cells 10. 
(E) C5orf56-IRF1-IL5 region. PCHi-C data shown for neutrophils 10. 
(F) BACH2 region. PCHi-C data shown for naive CD4 T cells 10. 
(G) LPP-BCL6 region. PCHi-C data shown for total B cells 10. 
 (H) GPA33 region. PCHi-C data shown for neutrophils 10. 











Supplementary Figure 8. Locus zoom plots for loci associated with 
EGPA. Strength of association with EGPA and LD structure relative to the 
lead SNP at each locus. All EGPA vs controls: A) BCL2L11, B) TSLP, C) Chr 
10, D) CDK6,  E) IRF1/IL5, F) BACH2, G) LPP. ANCA –ve EGPA vs controls:  
H) GPA33. MPO+ vs controls: I) Chr 12 intergenic region.  
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Supplementary Figure 9. Genetic effects on eosinophil count correlate 
with risk of EGPA. Of the 209 conditionally independent genetic variants 
associated with peripheral blood eosinophil count in the analysis by Astle et al 
11, 193 (92%) were typed or imputed with INFO score >0.7 in the EGPA 
dataset. The point estimates for the effect sizes on eosinophil count and on 
EGPA risk for these 193 SNPs are shown here. Each circle represents a 
genetic variant. 95% confidence intervals are indicated by the horizontal and 
vertical bars. The effect size for eosinophil count (x-axis) is the coefficient (the 
‘beta’) for the genotype term in the meta-analysis by Astle et al. The y-axis 
shows the estimation of the log (OR) in the EGPA GWAS. For details of 
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Supplementary Figure 10. The TSLP promoter region variant rs1837253 
has a greater effect size in EGPA than in asthma. Forest plot comparing 
odds ratio estimates from genome-wide association studies of asthma to 
EGPA. Black squares indicate estimated odds ratios (also printed numerically 
in the column to the left of the plot). Horizontal lines indicate 95% confidence 
intervals. Asthma studies are indicated by the name of the first author, with 
the ancestry of the cohort studied in parentheses. EGPA OR and confidence 

























Supplementary Figure 11. QQ plots of genetic associations in EGPA 
according to association in IBD. A) All EGPA cases vs controls. B) ANCA –
ve EGPA vs controls. C) MPO+ EGPA vs controls. Black circles indicate all 
genetic variants in the EGPA study. Red circles represent the subset of 
genetic variants with genome-wide significance (P <5x10-8) in IBD. IBD 
summary statistics were taken from the GWAS by Liu et al 12(European-
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Supplementary Figure 12. Amino acid positions in HLA-DRB1, HLA-
DQA1 and HLA-DQB1 associated with susceptibility to EGPA. Amino acid 
positions in HLA-DRB1, HLA-DQA1 and HLA-DQB1 associated with 
susceptibility to EGPA (A) and following conditioning on position 74 in HLA-







































































































































































































































































































































































































































































Supplementary Figure 13. Forest plot of Mendelian randomization 
estimates for the causal effect of eosinophil count on EGPA. Point 
estimates with 95% confidence intervals are shown for multiple Mendelian 
randomization methods. MR analysis performed using P-values for all EGPA 
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Supplementary Figure 14. Principal components analysis (PCA) of 
genotype data. PCA plots show ancestry of EGPA patients and controls 
(before removal of non-European ancestry individuals) in relation to 1000 
Genomes Project individuals. EGPA patients and controls are coloured dark 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 15. QQ plots for all EGPA cases vs controls using 
logistic regression (SNPTEST software).	(A) Directly genotyped variants. 
(B) Directly genotyped variants and imputed SNPs with ‘info’ metric >0.9. The 







Supplementary Table 1. Criteria for the diagnosis of EGPA from the ‘Study to Investigate Mepolizumab in the 
Treatment of Eosinophilic Granulomatosis With Polyangiitis’ (MIRRA$) 
A diagnosis of EGPA requires both: 
-Asthma 
AND 
-Eosinophilia (>1.0x109/L and/or >10% of total blood leucocytes) 
PLUS at least 2 of the following additional features of EGPA: 
 
Positive biopsy A biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular 
eosinophilic infiltration, or eosinophil-rich granulomatous inflammation. 
Neuropathy Either mononeuritis or polyneuropathy demonstrated by a motor deficit or nerve conduction 
abnormality 
Pulmonary infiltrates Non-fixed 
Sino-nasal abnormality  
Cardiomyopathy Established by echocardiography or cardiac magnetic resonance imaging 
Glomerulonephritis Hematuria, red cell casts, proteinuria 
Alveolar haemorrhage Confirmed by bronchoalveolar lavage 
Palpable purpura  






























Supplementary Table 2. Breakdown of 534 cases and 6688 controls by 
country (primary cohort). 
Country Cases Controls 
United Kingdom and Republic of Ireland 97 5465 (EPIC) 
Germany 147 273 
Czech Republic 5 130 
Poland 48 118 
France 68 0 
Italy 119 266 
Spain 29 93 
Sweden 21 343 
UK controls from the European Prospective Investigation into Cancer and 




Supplementary Table 3. Ethics approval from each contributing centre 
Centre/DNA bank Ethics number Ethics committee 
Overarching GWAS ethics 10/H0308/1 Cambridgeshire 2 Research Ethics Committee 
Watts DNA bank MREC 03/0/118 MREC for Scotland 
University of Erlangen-Nuremberg No. 3604 Ethics Committee of the University of Erlangen-Nuremberg 
Poland KBET/201/B/2011 Jagiellonian University Ethics Committee 
Klinikum Bad Bramstedt AZ 13-114 Ethics Committee of the University of Lübeck 
Lund University Dnr 2010/29 The Regional Ethical Review Board, Lund, Sweden 
University Hospital of Parma 29932-08/10/2008 Ethics Committee of Parma University Hospital 
Paris 2009-A01331-56 Comite de Protection des Personnes Ile de France X 
Karolinska University Hospital 2008/1143-31 Regional Ethics Committee in Stockholm. 
Hospital Clinic Barcelona HCB/2016/0274  Ethics committee of the Hospital Clínic of Barcelona 
San Raffaele Hospital - Milan Autoimmuno-mol 
Protocol 
Ethics Committee of San Raffaele Hospital, Milan, Italy 
Uppsala University 2011/241/2 Regional Ethics Committee in Uppsala, Sweden 
University Hospital Prague 1738/07 (S-IV) Ethics Committee of the General University Hospital in Prague 
St James’s Hospital, Dublin 01/03/2010 SJH/AMNCH Research Ethics Committee  
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Supplementary Table 4. Direction of effect at EGPA-associated non-HLA variants on eosinophil count and asthma risk 


















rs72946301 2:111861838 imputed ACOXL intron variant; 
ACOXL-AS1 (antisense RNA) non-
coding transcript variant; 
MIR4435-2HG (lincRNA) non-coding 
variant 
A (minor) é na é† 
 
rs9290877$ 3:188442480 typed LPP intron variant, non-coding 
transcript variant, upstream gene 
variant 
C (minor) é na é 
rs1837253 5:110401872 typed TSLP upstream gene variant C (major) é é é 
rs11745587$ 5:131796922 typed C5orf56 non-coding transcript variant, 
intron variant, 
downstream gene variant; 
AC116366.3 intron variant, non-coding 
transcript variant 
A (minor) é é é 
rs6454802$ 6:90814199 typed BACH2 intron variant, non-coding 
transcript variant 
C (major) é é é 
rs42041$ 7: 92246744 typed CDK6 intron variant, non-coding 
transcript variant 
G (minor) é na NS 
rs34574566 10:9042745 imputed Intergenic variant CT (major) é na na 
rs72689399 
 
1:167038121 imputed GPA33 intron variant, 
non-coding transcript variant, 
NMD transcript variant 
T (minor) NS NS NS 
rs78478398 12:80428530 imputed Intergenic variant C (minor) NS NS NS 
* from Ensembl Variant Effect Predictor tool; na, variant or an LD proxy not available; NS, not significant; UTR, untranslated region; NMD, nonsense-
mediated decay; $significant by cFDR; † P not genome-wide significant (P 7.7x10-5). Blue shading indicates the association was identified in the GWAS 




Supplementary Table 5. Replication cohort case demographics by country of origin	
	
 Germany Italy 
Number 49 101 
Gender (M/F) 16/33 43/58 
ANCA -ve 42 56 
ANCA +ve 6 43 








Supplementary Table 6. Meta-analysis of genetic associations with EGPA in the primary and replication cohorts 
 Total EGPA 
 
 
 Primary cohort 
N = 534 cases 
N = 6688 controls 
Replication cohort 
N = 142 cases 
N = 121 controls 
Combined cohort 
N = 676 cases 
N = 6809 
Chr SNP Gene P Beta P Beta P Beta 
2 rs72946301 BCL2L11 1.9x10-10 0.59 0.02 0.61 9.0x10-11 0.59 
5 rs1837253 TSLP 1.5x10-10 0.41 0.02 0.51 5.2x10-11 0.42 
6 rs9274704 HLA-DQ 8.2x10-16 0.69 2.5x10-5 0.80 1.2x10-20 0.70 











Total* % MPO 
positive 
Czech Republic 2 3 5 60.0 
France 48 19 68 27.9 
Germany 124 22 147 15.0 
Italy 56 57 119 47.9 
Poland 36 5 48 10.4 
Spain 12 16 29 55.2 
Sweden 12 9 21 42.9 
UK & Republic of 
Ireland 
62 28 97 28.9 
 
*total is greater than sum of MPO+ and ANCA –ve because of patients with PR3 ANCA or positive ANCA immunofluorescence 
without MPO or PR3 antibodies 
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Supplementary Table 8: associations of ANCA status with clinical features using logistic regression with adjustment for 
country of origin. 
 
Clinical feature Nominal P value Bonferroni adjusted P 
value 
Odds ratio (95% CI) 
Neuropathy 2.29x10-5 1.83x10-4 2.69 (1.70, 4.26) 
Lung infiltrates 0.0029 0.023 0.51 (0.33, 0.80) 
ENT 0.41 1.0 0.80 (0.46, 1.37) 
Cardiomyopathy 0.00055 4.36x10-3 0.39 (0.23, 0.67) 
Glomerulonephritis 3.85x10-6 3.08x10-5 3.87 (2.18, 6.87) 
Lung haemorrhage 0.47 1.0 1.46 (0.52, 4.08) 
Purpura 0.15 1.0 0.70 (0.43, 1.13) 
Positive biopsy 0.52 1.0 0.87 (0.57, 1.33) 
 
Analysis confined to ANCA –ve and MPO ANCA +ve patients (n = 352+159= 511). Patients who were PR3 ANCA positive, or who 
were ANCA positive by immunofluorescence without MPO or PR3 antibodies were excluded. Odds ratios are for MPO autoantibody 
positivity (i.e. positive odds ratios indicate increased prevalence of the clinical feature in MPO antibody positive cases). Significant 
associations are highlighted in bold.   
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Supplementary Table 9. Meta-analysis of genetic associations with EGPA subsets in the primary and replication cohorts 
EGPA subset 	 	 	 Primary	cohort	 Replication	cohort	 Combined	cohort	
 Chr	 Gene	 SNP	 P	 Beta	 P	 Beta	 P	 Beta	
MPO	+ve	
EGPA*	
	 	 	 	 	 	 	 	 	
	 6	 HLA-DQ	 rs17212014	 5.9x10-34	 2.15	 1.2x10-7	 1.53	 1.1x10-41	 2.0	
	 12	 12q21	 rs78478398	 1.7x10-8	 1.87	 0.25	 0.71	 1.3x10-8	 1.62	
ANCA	–ve	
EGPA^	
	 	 	 	 	 	 	 	 	
	 1	 GPA33	 rs72689399	 1.1x10-9	 1.86	 0.27	 1.06	 7.4x10-10	 1.78	






Supplementary Table 10. Evidence to support biological plausibility of EGPA-associated variants 
 
















Experimental data Other 
1 rs72689399 
 
- GPA33 Yes circumstantial GPA33 plays a role in 
maintaining epithelial barrier 
function; KO mice exhibit 
increased intestinal 
permeability and increased 
severity of DSS-induced colitis 
14 
 




for asthma in 






BCL2L11 Yes strong KO mouse: defective apoptosis 
of immune cells; autoimmunity 
15-18 
 
MORRBID No  strong MORRBID KO: deficient in 
eosinophils. 19 
 
MORRBID regulates myeloid 
cell survival via BCL2L11 
expression 19 
 
MORRBID expression higher 
in HES patients cf controls. 19 
 
MORRBID expression 
correlates with IL5 expression. 
19 
 
ACOXL No - -  







BCL6 No strong BCL6-deficient mice die of 
overwhelming eosinophilic 
inflammation characterized by 
myocarditis and pulmonary 
vasculitis 20 
GWAS signals for allergy and 
immune-mediated diseases in 
this region at variants 















strong TSLP drives eosinophilia and 
enhanced TH2 responses 
through effects on mast cells, 
group 2 innate lymphoid cells 
(ILC2), and dendritic cells 
Drugs targeting TSLP in 
development for asthma 22,23 
 
GWAS signals for other 
eosinophilic diseases in this 
region at variants independent 
of EGPA hit 24-31 
 














IRF1 Yes  
 





strong Archetypal “eosinophilic” 
cytokine 32,33 
RCT evidence for anti-IL5 
therapy in EGPA and 
eosinophilic asthma 8,34 
 
C5orf56 Yes  no -  
IL4 No strong   










BACH2 Yes strong In B cells, BACH2 represses 
the transcriptional regulator 
BLIMP1. 35 
 
BACH2 also influences 
multiple facets of T cell 
differentiation and activity 36,37 
 
 48 
BACH2 deficient mice die of 
eosinophilic pneumonitis 38 




CDK6 Yes intermediate Plays a role in cell cycle 
regulation 
 








strong GATA3 activation is a key 
event for Th2 cell 
differentiation and 
development 39-42).  
 
Directly binds Th2 locus genes 
and drives pro-eosinophilic 
cytokines 42 
 
GATA3 overexpression leads 
to eosinophilia in mice 43 
 
GATA3 important for 
development and function of 




12 rs78478398 - PPP1R12A No - - - 
OTOGL Yes - - - 
 
Abbreviations: EC eosinophil count, IBD inflammatory bowel disease, JIA juvenile idiopathic arthritis, PSC primary sclerosing cholangitis 
* for comprehensive listings of disease associations and eQTLs that overlap with the EGPA-associated variants or their LD proxies, see Supplemental Data 
Items 1 and 2 
































Supplementary Table 11: Association of classical MHC alleles with MPO+ve EGPA 
MHC Allele Unconditioned Conditioned on 





 OR P OR P OR P OR P 
HLA-DRB1*08:01 35.8 7.6x10-24 - - - - - - 
HLA-DQA1*04:01 26.6 1.7x10-21 1.1 0.90 1.4 0.84 1.23 0.93 
HLA-DQB1*04:02 24.6 5.2x10-21 1.3 0.96 1.8 0.57 1.64 0.69 
HLA-DQA1*02:01 4.8 1.8x10-15 5.1 3.5x10-16 - - - - 
HLA-DRB1*07:01 4.7 2.7x10-15 5.1 4.8x10-16 1.1 0.98 1.09 0.99 
HLA-DQB1*03:03 4.5 1.9x10-7 5.3 7.9x10-9 2.6 3.3x10-3 2.71 0.002 
HLA-DQA1*05:01 0.4 1.2x10-8 0.5 3.2x10-6 0.6 2.0x10-3 0.63 9.0x10-4 
HLA-DQB1*02:02 3.4 2.3x10-8 3.4 3.8x10-8 0.5 0.13 0.48 0.097 
HLA-DRB1*01:03 11.4 7.5x10-7 13.7 5.7x10-8 14.0 4.2x10-8 - - 
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Supplementary Table 12. Minor allele frequencies at HLA alleles associated with EGPA stratified by country 
HLA	allele	 Total	
cohort	 Czech	 UK	 Germany	 Italy	 Poland	 Spain	 Sweden	
	 	 Case	 Cont	 Case	 Cont	 Case	 Cont	 Case	 Cont	 Case	 Cont	 Case	 Cont	 Case	 Cont	 Case	 Cont	
HLA	DQA1	 02:01	 0.19	 0.13	 0.30	 0.15	 0.23	 0.14	 0.13	 0.09	 0.22	 0.13	 0.16	 0.17	 0.29	 0.16	 0.14	 0.07	
	 04:01	 0.07	 0.02	 0.10	 0.02	 0.04	 0.02	 0.06	 0.02	 0.09	 0.02	 0.05	 0.03	 0.10	 0.03	 0.12	 0.04	
HLA	DQB1	 02:02	 0.13	 0.10	 0.10	 0.08	 0.17	 0.10	 0.09	 0.07	 0.17	 0.10	 0.13	 0.12	 0.22	 0.14	 nd	 0.05	
	 04:02	 0.07	 0.02	 0.10	 0.02	 0.04	 0.02	 0.06	 0.02	 0.09	 0.03	 0.05	 0.03	 0.10	 0.03	 0.12	 0.04	
	 03:03	 0.06	 0.05	 0.20	 0.07	 0.08	 0.05	 0.04	 0.04	 0.05	 0.04	 0.04	 0.05	 0.07	 0.02	 0.19	 0.05	
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